dc.contributor.author | Šťovíčková, Lucie | |
dc.contributor.author | Hansíková, Hana | |
dc.contributor.author | Hadžić, Haris | |
dc.contributor.author | Strnad, Pavel | |
dc.contributor.author | Novotná, Ludmila | |
dc.contributor.author | Šimčík, Martin | |
dc.contributor.author | Mušová, Zuzana | |
dc.contributor.author | Vyhnálek, Martin | |
dc.contributor.author | Paulasová - Schwabová, Jaroslava | |
dc.contributor.author | Zumrová, Alena | |
dc.date.accessioned | 2024-09-10T18:15:29Z | |
dc.date.available | 2024-09-10T18:15:29Z | |
dc.date.issued | 2022 | |
dc.identifier.uri | https://hdl.handle.net/20.500.14178/2607 | |
dc.description.abstract | Title: Presentation of a cohort of 40 Czech and Slovak patients with Friedreich's ataxia with the aim of introducing innovative therapiesBackground and objectives: Friedreich's ataxia (FA) is an autosomal recessive inherited disease caused by a mutation in the FXN gene for the mitochondrial protein frataxin. As a result of its dysfunction, both neurological symptoms and non-constant damage to other tissues or organs are manifested. Since 1999, 76 genetically confirmed Czech and Slovak patients have been examined at the Center of Hereditary Ataxia in Prague (40 active; 20 died; 16 lost in follow-up). Our aim was to correlate clinical data monitoring the natural course of the disease with metabolic and genetic markers in order to prepare for the application of targeted biological / gene therapies.Methods: Patients with genetically confirmed FA were neurologically examined and underwent clinical assessment including the Scale for the Assessment and Rating of Ataxia (SARA); Activities of Daily Living (ADL); Inventory of Non-Ataxia Signs (INAS); Spino-Cerebellar Ataxia Functional Index (SCAFI); Montreal Cognitive Assessment (MoCA); quality of life assessments; neurocognitive tests; and specific laboratory tests including biosampling, mitochondrial function in isolated platelets (spectrophotometry method) and genetic analysis of the FXN gene by determining the length of GAA expansions (long-range polymerase chain reaction (PCR) with PCR product analysis on an Agilent 4200 TapeStation system).Results: A total of 40 patients with FA were examined with a comprehensive protocol in the period 08/2021 to 06/2022 and their data were entered into the EFACTS registry (European Friedreich's Ataxia Consortium for Translational Studies). Their mean age was 32.3 (8-72) years (6 of them under 18), 22 male / 18 female; average ADL 15.4 (2-27) out of 36 total; average SARA 22.6 (7-40) out of 40 total. The activity of respiratory chain complexes in isolated platelets in 26 patients with Friedreich's ataxia and controls shows decreased cytochrome c oxidase (COX) activity and decreased COX / CS (CS - citrate synthase) ratio.Conclusion: We present a well-defined cohort of Czech patients with FA, which has recently been included in the EFACTS registry and is ready for clinical trials. Further biochemical analysis and longitudinal follow-up is ongoing. | en |
dc.language.iso | en | |
dc.relation.url | https://eveeno.com/agiconference2022 | |
dc.rights | Plný text výsledku je zpřístupněn v repozitáři pouze přihlášeným uživatelům Univerzity Karlovy, pouze pro čtení. Dále lze plné texty z repozitáře stahovat, případně tisknout, ale pouze pro osobní potřebu (viz § 30 zákona č. 121/2000 Sb., autorského zákona). | cs |
dc.rights | The fulltext is published in the repository only for authenticated Charles University users as read-only. Authenticated Charles University users are entitled to download and print the fulltext published without a licence for their personal use only (in accordance with § 30 of Act No. 121/2000 Coll., the Copyright Act). | en |
dc.title | Correlation of genotype, phenotype and mitochondrial metabolism of patients with Friedreich's ataxia with the aim of implementing innovative therapies | en |
dcterms.accessRights | restrictedAccess | |
dc.date.updated | 2024-09-10T18:15:28Z | |
dc.subject.keyword | Friedreich’s ataxia | en |
dc.subject.keyword | genotype | en |
dc.subject.keyword | phenotype | en |
dc.subject.keyword | mitochondrial metabolism | en |
dc.subject.keyword | cytochrome c oxidase (COX) | en |
dc.subject.keyword | citrate synthase (CS) | en |
dc.subject.keyword | NADH-decylubiquinone oxidoreductase (NQR), succinate decylubiquinone DCPIP reductase (SQR) | en |
dc.relation.fundingReference | info:eu-repo/grantAgreement/UK/GAUK/GAUK309121 | |
dc.relation.fundingReference | info:eu-repo/grantAgreement/MSM//LX22NPO5107 | |
dc.date.embargoStartDate | 2024-09-10 | |
dc.date.embargoEndDate | 2023-01-01 | |
dc.contributor.organizer | Ataxia Global Ïnitiative | |
dc.type.obd | 81 | |
dc.type.version | info:eu-repo/semantics/acceptedVersion | |
dc.identifier.obd | 625648 | |
dc.subject.rivPrimary | 30000::30100::30103 | |
dc.subject.rivSecondary | 30000::30100 | |
uk.faculty.primaryId | 109 | |
uk.faculty.primaryName | 2. lékařská fakulta | cs |
uk.faculty.primaryName | Second Faculty of Medicine | en |
uk.faculty.secondaryId | 108 | |
uk.faculty.secondaryId | 53 | |
uk.faculty.secondaryId | 52 | |
uk.faculty.secondaryName | 1. lékařská fakulta | cs |
uk.faculty.secondaryName | First Faculty of Medicine | en |
uk.faculty.secondaryName | Všeobecná fakultní nemocnice v Praze | cs |
uk.faculty.secondaryName | Všeobecná fakultní nemocnice v Praze | en |
uk.faculty.secondaryName | Fakultní nemocnice v Motole | cs |
uk.faculty.secondaryName | Motol University Hospital | en |
uk.department.primaryId | 1677 | |
uk.department.primaryName | Klinika dětské neurologie | cs |
uk.department.primaryName | Klinika dětské neurologie | en |
uk.department.secondaryId | 109 | |
uk.department.secondaryId | 1522 | |
uk.department.secondaryId | 100010693809 | |
uk.department.secondaryId | 100010692538 | |
uk.department.secondaryId | 5000002603 | |
uk.department.secondaryId | 100010692569 | |
uk.department.secondaryId | 1682 | |
uk.department.secondaryName | 2. lékařská fakulta | cs |
uk.department.secondaryName | Second Faculty of Medicine | en |
uk.department.secondaryName | Klinika pediatrie a dědičných poruch metabolismu 1. LF a VFN | cs |
uk.department.secondaryName | Department of Paediatrics and Inherited Metabolic Disorders 1. LF UK a VFN | en |
uk.department.secondaryName | Ústav biologie a lékařské genetiky 2. LF UK a FN Motol | cs |
uk.department.secondaryName | Department of Biology and Medical Genetics, 2nd Faculty of Medicine and Motol University Hospital | en |
uk.department.secondaryName | Klinika dětské neurologie 2. LF UK a FN Motol | cs |
uk.department.secondaryName | Department of paediatric Neurology, 2nd Faculty of Medicine and Motol University Hospital | en |
uk.department.secondaryName | Klinika pediatrie a dědičných poruch metabolismu 1.LF a VFN | cs |
uk.department.secondaryName | Klinika pediatrie a dědičných poruch metabolismu 1.LF a VFN | en |
uk.department.secondaryName | Neurologická klinika 2. LF UK a FN Motol | cs |
uk.department.secondaryName | Department of Neurology, 2nd Faculty of Medicine and Motol University Hospital | en |
uk.department.secondaryName | Neurologická klinika | cs |
uk.department.secondaryName | Department of Neurology | en |
uk.event.name | Ataxia Global Conference 2022 | |
dc.type.obdHierarchyCs | PŘEDNÁŠKA, POSTER::přednáška nebo poster::poster | cs |
dc.type.obdHierarchyEn | LECTURE, POSTER::lecture or poster::poster | en |
dc.type.obdHierarchyCode | 81::145::340 | en |
uk.displayTitle | Correlation of genotype, phenotype and mitochondrial metabolism of patients with Friedreich's ataxia with the aim of implementing innovative therapies | en |